Compare AbbVie Inc (ABBV) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Salesforce Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Salesforce Inc trades at $166.27 (market cap $138.84B). The key difference: AbbVie Inc is far larger — about 3.2× Salesforce Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CRM | |
|---|---|---|
Market Cap | $449.91B | $138.84B |
Sector | Health | Technology |
52-Week High | $261.07 | $273.65 |
52-Week Low | $184.85 | $150.12 |
Enterprise Value | $513.38B | $168.88B |
Dividend Yield | 2.72% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Salesforce (CRM) trades at $166.00, up 0.21% on the day, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals with a P/E of 19.64, revenue of $37.90 billion for 2025, and net income of $6.20 billion, supported by consistent earnings beats. Recent news highlights AI momentum and a significant year-to-date decline, with analyst consensus remaining strongly positive.
Outlook is favorable due to robust profitability, AI integration, and a consensus price target of $235.20, implying over 40% upside. Risks include market volatility, competitive pressures in SaaS, and macroeconomic headwinds affecting tech stocks, but strong cash flow and institutional support provide a solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
